Top
Retinitis Pigmentosa - Healing Genes
1251
post-template-default,single,single-post,postid-1251,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Retinitis Pigmentosa

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa (PIONEER)

A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa


Phase 1 / 2

DESCRIPTION:

Researchers at the University of Pittsburgh Medical Center are recruiting Retinitis Pigmentosa patients for an investigation of a gene therapy designed to impart a gene to correct the disease. The treatment would require a single intravitreal (into the retina) injection of the drug, a genetically modified and harmless virus. The patient would also undergo a light-stimulation treatment and follow up for 1 year.


PATIENT MUST:

  • Be 18 to 75 years of age
  • Have diagnosis of non-syndromic RP
  • Not have a prior vitrectomy or vitreomacular surgery

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Intravitreal injection of the gene therapy at one of several dose levels.
  3. Undergo light-stimulation therapy and follow up for 1 year.

LOCATIONS AND CONTACTS:
The study site is at the UPMC Eye Center in Pittsburgh, PA. Map.
Contacts:
Barrett Katz, MD  |  +1 646 831 3799  |  [email protected]
 
SPONSOR INFORMATION:
GenSight Biologics
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT03326336

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader